297 related articles for article (PubMed ID: 35454037)
1. Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion.
Hernandez M; Sullivan RD; McCune ME; Reed GL; Gladysheva IP
Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35454037
[TBL] [Abstract][Full Text] [Related]
2. Suppression of Cardiogenic Edema with Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Mechanisms and Insights from Pre-Clinical Studies.
Sullivan RD; McCune ME; Hernandez M; Reed GL; Gladysheva IP
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009562
[TBL] [Abstract][Full Text] [Related]
3. Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost-Benefit Analysis.
Glover S; Borrego ME; Ray GM; Roberts MH
Clinicoecon Outcomes Res; 2022; 14():465-477. PubMed ID: 35845354
[TBL] [Abstract][Full Text] [Related]
4. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
Al Rifai M; Newby LK; Nair AP; Misra A; Rogers JG; Fedson S; Virani SS
Curr Atheroscler Rep; 2022 Aug; 24(8):627-634. PubMed ID: 35653033
[TBL] [Abstract][Full Text] [Related]
5. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
[TBL] [Abstract][Full Text] [Related]
6. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
[TBL] [Abstract][Full Text] [Related]
7. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
Nassif ME; Kosiborod M
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
[TBL] [Abstract][Full Text] [Related]
8. The Role of Congestion Biomarkers in Heart Failure with Reduced Ejection Fraction.
Correale M; Fioretti F; Tricarico L; Croella F; Brunetti ND; Inciardi RM; Mattioli AV; Nodari S
J Clin Med; 2023 Jun; 12(11):. PubMed ID: 37298029
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
10. The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review.
Giri Ravindran S; Kakarla M; Ausaja Gambo M; Yousri Salama M; Haidar Ismail N; Tavalla P; Uppal P; Mohammed SA; Rajashekar S; Hamid P
Cureus; 2022 May; 14(5):e25476. PubMed ID: 35800782
[TBL] [Abstract][Full Text] [Related]
11. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure.
Vaduganathan M; Greene SJ; Zhang S; Solomon N; Chiswell K; Devore AD; Butler J; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Mcdermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Fonarow GC
J Card Fail; 2022 Apr; 28(4):554-563. PubMed ID: 34785402
[TBL] [Abstract][Full Text] [Related]
12. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
13. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
Butler J; Handelsman Y; Bakris G; Verma S
Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
[TBL] [Abstract][Full Text] [Related]
14. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
15. Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction.
Elserafy AS; Reda A; Farag E; Mostafa T; Farag N; Elbahry A; Sanad O; Bendary A; Elkersh A; Attia I; Selim M; Khamis H; Issak ER
Clin Drug Investig; 2021 Dec; 41(12):1027-1036. PubMed ID: 34780022
[TBL] [Abstract][Full Text] [Related]
16. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
[TBL] [Abstract][Full Text] [Related]
18. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.
Natali A; Nesti L; Tricò D; Ferrannini E
Cardiovasc Diabetol; 2021 Sep; 20(1):196. PubMed ID: 34583699
[TBL] [Abstract][Full Text] [Related]
19. Effects of SGLT-2 inhibitors on health-related quality of life and exercise capacity in heart failure patients with reduced ejection fraction: A systematic review and meta-analysis.
He Z; Yang L; Nie Y; Wang Y; Wang Y; Niu X; Bai M; Yao Y; Zhang Z
Int J Cardiol; 2021 Dec; 345():83-88. PubMed ID: 34653575
[TBL] [Abstract][Full Text] [Related]
20. Clinical Implications of Functional Mitral Regurgitation Severity in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF).
Naser N
Med Arch; 2022 Feb; 76(1):17-22. PubMed ID: 35422569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
